Vadodara based Alembic Pharmaceuticals has posted a 2.4 per cent rise in net profit for the first quarter of the fiscal ended June 30, 2012 at Rs 27.28 crore on the back of a 14 per cent rise in its domestic formulations sales and a 37 per cent growth in active pharmaceutical ingredients (API) exports . Net sales for the quarter under review stood at Rs 340.7 crore, up 5.5 per cent from Rs 322.7 crore in the year-before period.
On a consolidated basis, the company posted a 12 per cent rise in net profit to Rs 30.83 crore in Q1FY13, up from Rs 27.56 crore in the corresponding quarter in 2011-12 fiscal. Net sales was up 7 per cent to Rs 368 crore during the quarter under review against Rs 345 crore in corresponding quarter last year.
Domestic formulations sales was up 14 per cent during the quarter at Rs 197 crore against Rs 172 crore in the same period a year before. Formulation export sales were up marginally at Rs 139 crore during the quarter from Rs 137 crore in Q1FY12. For the quarter, API exports stood at Rs 83.48 crore against Rs 60.73 crore in the year-before period.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
